Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Macy's, Inc.M · Entity 3820 | SVP,Controller/ERM & Int. CFO | July 09, 2020 | July 10, 2020 |
| NEOGENOMICS INCNEO · Entity 2096 | Director | June 01, 2026 | June 03, 2026 |
| Paycom Software, Inc.PAYC · Entity 3498 | Director | May 05, 2025 | May 07, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Macy's, Inc.
Report date July 09, 2020 · Filed July 10, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 52,790 |
Reported balance
After 2020-07-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2020-07-09 · Grant · Acquired 52,790 · Balance 52,790 F1: Each restricted stock unit represents the equivalent of one share of the Issuer's common stock. F2: The restricted stock units vest one-fourth on each of the first, second, third and fourth anniversaries of the date granted. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the equivalent of one share of the Issuer's common stock.
F2: The restricted stock units vest one-fourth on each of the first, second, third and fourth anniversaries of the date granted.
NEOGENOMICS INC
Report date June 01, 2026 · Filed June 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,237 |
Reported balance
After 2026-06-01 transaction · row 1
1 source rowRow 1 · 2026-06-01 · Exercise / conversion · Acquired 23,077 · Balance 30,237 F1: Reflects release of restricted stock units that were previously reported on a Form 4. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-01 · Exercise / conversion · Disposed 23,077 · Balance 0 F2: Once vested, the shares of common stock are not subject to expiration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 15,970 |
Reported balance
After 2026-06-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-01 · Grant · Acquired 15,970 · Balance 15,970 F2: Once vested, the shares of common stock are not subject to expiration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.52 · Expires 2036-06-01 | Direct | 11,069 |
Reported balance
After 2026-06-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-01 · Grant · Acquired 11,069 · Balance 11,069 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.59 · Expires 2034-06-01 | Direct | 5,430 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · Balance 5,430 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.28 · Expires 2035-06-01 | Direct | 16,107 |
Reported balance
Holding disclosure · report date 2026-06-01 · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · Balance 16,107 |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects release of restricted stock units that were previously reported on a Form 4.
F2: Once vested, the shares of common stock are not subject to expiration.
Paycom Software, Inc.
Report date May 05, 2025 · Filed May 07, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,706 |
Reported balance
After 2025-05-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2025-05-05 · Grant · Acquired 1,099 · Balance 3,706 F1: Represents shares of restricted stock granted to the reporting person under the Paycom Software, Inc. 2023 Long-Term Incentive Plan. F2: Includes 2,315 unvested shares of restricted stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of restricted stock granted to the reporting person under the Paycom Software, Inc. 2023 Long-Term Incentive Plan.
F2: Includes 2,315 unvested shares of restricted stock.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Anywhere Real Estate Inc.
Report date January 09, 2026 · Filed January 09, 2026
Section 16 reporting ended · disclosed 2026-01-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.01 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-01-09 transaction · row 1
1 source rowRow 1 · 2026-01-09 · Disposition to issuer · Disposed 134,617 · Balance 0 F1: On January 9, 2026, pursuant to the previously announced Agreement and Plan of Merger, dated as of September 22, 2025 (the Merger Agreement), by and among Anywhere Real Estate Inc. (the Company), Compass, Inc. (Compass), and Velocity Merger Sub, Inc., a wholly owned subsidiary of Compass (Merger Sub), Merger Sub merged with and into the Company (the Merger), with the Company surviving the Merger as a wholly owned subsidiary of Compass. F2: Pursuant to the Merger Agreement, each share of Company common stock, par value $0.01 per share issued and outstanding immediately prior to the effective time of the Merger (the Effective Time), was converted into the right to receive 1.436 fully paid and nonassessable shares (the Exchange Ratio) of class A common stock of Compass (the Compass Shares) and, if applicable, cash in lieu of fractional shares. F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU award was canceled and converted into a RSU award in respect of Compass Shares covering that number of Compass Shares equal to the product of (i) the number of shares of Company common stock subject to the award multiplied by (ii) the Exchange Ratio. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 9, 2026, pursuant to the previously announced Agreement and Plan of Merger, dated as of September 22, 2025 (the Merger Agreement), by and among Anywhere Real Estate Inc. (the Company), Compass, Inc. (Compass), and Velocity Merger Sub, Inc., a wholly owned subsidiary of Compass (Merger Sub), Merger Sub merged with and into the Company (the Merger), with the Company surviving the Merger as a wholly owned subsidiary of Compass.
F2: Pursuant to the Merger Agreement, each share of Company common stock, par value $0.01 per share issued and outstanding immediately prior to the effective time of the Merger (the Effective Time), was converted into the right to receive 1.436 fully paid and nonassessable shares (the Exchange Ratio) of class A common stock of Compass (the Compass Shares) and, if applicable, cash in lieu of fractional shares.
F3: Pursuant to the Merger Agreement, at the Effective Time, each outstanding RSU award was canceled and converted into a RSU award in respect of Compass Shares covering that number of Compass Shares equal to the product of (i) the number of shares of Company common stock subject to the award multiplied by (ii) the Exchange Ratio.
MERIDIAN BIOSCIENCE INC
Report date January 31, 2023 · Filed January 31, 2023
Section 16 reporting ended · disclosed 2023-01-31. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 1
1 source rowRow 1 · 2023-01-31 · Disposition to issuer · Disposed 10,274 · Balance 0 F1: The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.15 · Expires 2028-09-20 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-31 · Disposition to issuer · Disposed 12,000 · Balance 0 F2: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.97 · Expires 2029-01-04 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-01-31 · Disposition to issuer · Disposed 8,740 · Balance 0 F3: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.46 · Expires 2030-01-29 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-01-31 · Disposition to issuer · Disposed 17,205 · Balance 0 F4: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.36 · Expires 2031-01-27 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-01-31 · Disposition to issuer · Disposed 5,796 · Balance 0 F5: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.75 · Expires 2032-01-26 | Direct | 0 |
Reported balance
After 2023-01-31 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-01-31 · Disposition to issuer · Disposed 5,656 · Balance 0 F6: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares were disposed of pursuant to the Agreement and Plan of Merger dated as of July 7, 2022 (the "Merger Agreement") by and among the Issuer and SD Biosensor, Inc., a corporation with limited liability organized under the laws of the Republic of Korea whereby, immediately prior to the effective time of the merger contemplated therein (the "Effective Time"), all issued and outstanding shares of Issuer common stock were converted into the right to receive $34.00 per share in cash and, when so converted, automatically cancelled.
F2: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F3: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F4: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F5: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
F6: The Stock Option vested in full and was cancelled pursuant to the Merger Agreement in exchange for a cash payment representing the difference between the per share exercise price of the option and the $34.00 per share merger consideration, less all applicable deductions and withholdings required to be withheld in respect of such payment.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 21, 2019 Filed Mar 25, 2019 20:06 UTC | Macy's, Inc. M · Entity 3820 | GrantOption to Purchase Common Stock · Derivative | 19,455 | $0.00 Strike: $24.03 | $0.00 |
DisclosureSEC source: 0000794367-19-000019 · primary_doc.xml · derivative · entry 1 Williams Felicia · CIK 0001675737 · EVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,455 Underlying: Common Stock · 19,455 shares Expires 2029-03-21 F1 · derivative.exercise_date: Grant to reporting person of options to purchase 19,455 shares of common stock under the Issuer's 2018 Equity and Incentive Compensation Plan. The options become exercisable in 25% increments on March 21, 2020, March 21, 2021, March 21, 2022, and March 21, 2023. Read SEC document |
| January 24, 2019 Filed Jan 28, 2019 11:28 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantStock Options (Right to Buy) · Derivative | 8,740 | $0.00 Strike: $16.97 | $0.00 |
DisclosureSEC source: 0001127602-19-002783 · form4.xml · derivative · entry 2 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,740 Underlying: Common Stock · 8,740 shares Expires 2029-01-24 F2 · derivative.exercise_date: These options are awarded under the 2012 Stock Incentive Plan and vest 25% every 90 days from the date of grant. Read SEC document |
| January 24, 2019 Filed Jan 28, 2019 11:28 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantCommon Stock | 981 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-002783 · form4.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 981 F1 · shares: These restricted stock units are awarded under the 2012 Stock Incentive Plan and vest 25% every 90 days from the date of grant. Read SEC document |
| September 20, 2018 Filed Sep 24, 2018 16:28 UTC | MERIDIAN BIOSCIENCE INC VIVO · Entity 117499 | GrantStock Options (Right to Buy) · Derivative | 12,000 | $0.00 Strike: $15.15 | $0.00 |
DisclosureSEC source: 0001127602-18-028277 · form4.xml · derivative · entry 1 Williams Felicia · CIK 0001675737 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2028-09-20 F1 · derivative.exercise_date: This award vests 25% every 30 days from the date of grant. Read SEC document |
| April 06, 2018 Filed Apr 10, 2018 20:29 UTC | Macy's, Inc. M · Entity 3820 | GrantRestricted Stock Units · Derivative | 2,684 | $0.00 | $0.00 |
DisclosureSEC source: 0000794367-18-000044 · primary_doc.xml · derivative · entry 2 Williams Felicia · CIK 0001675737 · EVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,684 Underlying: Common Stock · 2,684 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Macy's, Inc. common stock. F3 · derivative.exercise_date: The restricted stock units vest one-fourth on each of the first, second, third and fourth anniversaries of the date granted. F3 · derivative.expiration_date: The restricted stock units vest one-fourth on each of the first, second, third and fourth anniversaries of the date granted. Read SEC document |
| April 06, 2018 Filed Apr 10, 2018 20:29 UTC | Macy's, Inc. M · Entity 3820 | GrantOption to Purchase Common Stock · Derivative | 10,652 | $0.00 Strike: $29.80 | $0.00 |
DisclosureSEC source: 0000794367-18-000044 · primary_doc.xml · derivative · entry 1 Williams Felicia · CIK 0001675737 · EVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,652 Underlying: Common Stock · 10,652 shares Expires 2028-04-06 F1 · derivative.exercise_date: Grant to reporting person of options to purchase 10,652 shares of common stock under the Issuer's Amended and Restated 2009 Omnibus Incentive Compensation Plan. The options become exercisable in 25% increments on April 6, 2019, April 6, 2020, April 6, 2021, and April 6, 2022. Read SEC document |
| March 28, 2018 Filed Mar 28, 2018 18:52 UTC | Macy's, Inc. M · Entity 3820 | SaleCommon Stock | 785 | $28.99 | $22,760.53 |
DisclosureSEC source: 0000794367-18-000026 · primary_doc.xml · nonDerivative · entry 2 Williams Felicia · CIK 0001675737 · EVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| March 27, 2018 Filed Mar 28, 2018 18:52 UTC | Macy's, Inc. M · Entity 3820 | Exercise / conversionRestricted Stock Units · Derivative | 785 | $0.00 | $0.00 |
DisclosureSEC source: 0000794367-18-000026 · primary_doc.xml · derivative · entry 3 Williams Felicia · CIK 0001675737 · EVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 785 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: One-for-one conversion. F2 · derivative.exercise_date: The reporting person was granted 785 restricted stock units on March 27, 2015, vesting March 27, 2018. F2 · derivative.expiration_date: The reporting person was granted 785 restricted stock units on March 27, 2015, vesting March 27, 2018. Read SEC document |
| March 27, 2018 Filed Mar 28, 2018 18:52 UTC | Macy's, Inc. M · Entity 3820 | Exercise / conversionCommon Stock | 785 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000794367-18-000026 · primary_doc.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · EVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 785 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: One-for-one conversion. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 14:14 UTC | Macy's, Inc. M · Entity 3820 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $24.85 | $0.00 |
DisclosureSEC source: 0000794367-18-000018 · primary_doc.xml · derivative · entry 3 Williams Felicia · CIK 0001675737 · EVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2018-03-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Grant to reporting person of options to purchase 10,000 shares of common stock under the Issuer's 1995 Executive Equity Incentive Plan. The options became exercisable in 25% increments on March 21, 2009, March 21, 2010, March 21, 2011, and March 21, 2012. Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 14:14 UTC | Macy's, Inc. M · Entity 3820 | SaleCommon Stock | 10,000 | $29.42 | $294,150.00 |
DisclosureSEC source: 0000794367-18-000018 · primary_doc.xml · nonDerivative · entry 2 Williams Felicia · CIK 0001675737 · EVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| March 02, 2018 Filed Mar 5, 2018 14:14 UTC | Macy's, Inc. M · Entity 3820 | Exercise / conversionCommon Stock | 10,000 | $24.85 | $248,500.00 |
DisclosureSEC source: 0000794367-18-000018 · primary_doc.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · EVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 22, 2017 Filed Nov 22, 2017 15:46 UTC | Macy's, Inc. M · Entity 3820 | GrantRestricted Stock Units · Derivative | 6,009 | $0.00 | $0.00 |
DisclosureSEC source: 0000794367-17-000128 · primary_doc.xml · derivative · entry 1 Williams Felicia · CIK 0001675737 · EVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,009 Underlying: Common Stock · 6,009 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Macy's, Inc. common stock. F2 · derivative.exercise_date: The restricted stock units vest one-third on each of the first, second and third anniversaries of the date granted. F2 · derivative.expiration_date: The restricted stock units vest one-third on each of the first, second and third anniversaries of the date granted. Read SEC document |
| November 20, 2017 Filed Mar 7, 2019 21:56 UTC Amendment | Macy's, Inc. M · Entity 3820 | GrantRestricted Stock Units · Derivative | 6,009 | $0.00 | $0.00 |
DisclosureSEC source: 0000794367-19-000018 · primary_doc.xml · derivative · entry 1 Williams Felicia · CIK 0001675737 · EVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,009 Underlying: Common Stock · 6,009 shares Expires not disclosed F1 · security: This amended Form 4 is being filed to correct the date the Restricted Stock Units were granted and become exercisable, which were previously reported incorrectly. As of November 20, 2017, the reporting person was granted 6,009 Restricted Stock Units, which all vest on the third anniversary of the date granted. F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Macy's, Inc. common stock. F3 · derivative.exercise_date: The restricted stock units all vest on the third anniversary of the date granted. F3 · derivative.expiration_date: The restricted stock units all vest on the third anniversary of the date granted. Read SEC document |
| March 29, 2017 Filed Mar 30, 2017 14:30 UTC | Macy's, Inc. M · Entity 3820 | SaleCommon Stock | 1,697 | $28.55 | $48,449.35 |
DisclosureSEC source: 0000794367-17-000045 · primary_doc.xml · nonDerivative · entry 2 Williams Felicia · CIK 0001675737 · EVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| March 28, 2017 Filed Mar 30, 2017 14:30 UTC | Macy's, Inc. M · Entity 3820 | Exercise / conversionRestricted Stock Units · Derivative | 1,697 | $0.00 | $0.00 |
DisclosureSEC source: 0000794367-17-000045 · primary_doc.xml · derivative · entry 3 Williams Felicia · CIK 0001675737 · EVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,697 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: One-for-one conversion. F2 · derivative.exercise_date: The reporting person was granted 1,697 restricted stock units on March 28, 2014, vesting was on March 28, 2017. F2 · derivative.expiration_date: The reporting person was granted 1,697 restricted stock units on March 28, 2014, vesting was on March 28, 2017. Read SEC document |
| March 28, 2017 Filed Mar 30, 2017 14:30 UTC | Macy's, Inc. M · Entity 3820 | Exercise / conversionCommon Stock | 1,697 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000794367-17-000045 · primary_doc.xml · nonDerivative · entry 1 Williams Felicia · CIK 0001675737 · EVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,697 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: One-for-one conversion. Read SEC document |
| March 24, 2017 Filed Mar 28, 2017 22:04 UTC | Macy's, Inc. M · Entity 3820 | GrantOptions to Purchase Common Stock · Derivative | 24,427 | $0.00 Strike: $28.17 | $0.00 |
DisclosureSEC source: 0000794367-17-000031 · primary_doc.xml · derivative · entry 1 Williams Felicia · CIK 0001675737 · EVP,Controller/Enterprise Risk 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,427 Underlying: Common Stock · 24,427 shares Expires 2027-03-24 F1 · derivative.exercise_date: Grant to reporting person of options to purchase 24,427 shares of common stock under the Issuer's Amended and Restated 2009 Omnibus Incentive Compensation Plan. The options become exercisable in 25% increments on March 24, 2018, March 24, 2019, March 24, 2020 and March 24, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.